Pfizer Will Review Cholesterol Drug Category To Gauge Longevity Of Slowdown

Pfizer's annual financial analysis will include a review of the cholesterol-lowering drug market to determine if a more than 50% drop in new prescription growth rates in the third quarter is a short-term or long-term effect, CEO Hank McKinnell said